EDT Kazia Therapeutics (KZIA) trading halted, news pendingStay Ahead of the Market: Discover outperforming stocks and invest smarter ...

1 Day KZIA -0.10% DJIA 0.08% Russell 2K -0.56% Health Care/Life Sciences 0.25% ...

Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast ...

Australian biotech Kazia Therapeutics (NASDAQ:KZIA) announced Tuesday that the U.S. FDA has indicated that data on overall survival from its GBM-AGILE study data would not be appropriate for ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...

Stay updated on market trends for KZIA. Kazia Therapeutics updates paxalisib's regulatory progress after FDA discussions on glioblastoma data, highlighting plans for a pivotal Phase 3 trial.

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...

Looking for the most shorted stocks?

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to ...